Protalix Biotherapeutics (PLX)CEO bought ~$101K

~$101K

Approx. value · 56K sh @ $1.81

189K

Holds after · shares reported

Traded

Dec 19, 2025

Filed

Dec 23, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 13, 2025Company filing · Form 8-K · ResultsReported its results
2. Nov 18, 2025InsiderDirector sold ~$314 of PLX shares in the open market
3. Dec 19, 2025 · this disclosureInsider · First buy since 2023CEO purchased ~$101K of PLX shares in the open market

What came next

1. Mar 18, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Protalix Biotherapeutics

OQRO holds no insider, Congress, fund or contract record for Protalix Biotherapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PLX page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Protalix Biotherapeutics

• SEC Form 4Nov 19, 2025
• SEC Form 4Aug 12, 2025

Everything OQRO holds on this company is on its PLX page.